US Stock MarketDetailed Quotes

Inhibikase Therapeutics (IKT)

Watchlist
  • 1.700
  • -0.010-0.58%
Close Apr 14 16:00 ET
  • 1.700
  • 0.0000.00%
Post 18:51 ET
224.46MMarket Cap-3.47P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Inhibikase Therapeutics (IKT) Revenue Breakdown Overview

By Business/Source

Currency:USD
2023/FY
Stock NameRevenueRatio
Developing protein kinase inhibitor therapeutics260.5K100.00%

By Country/Region

Currency:USD
2023/FY
Stock NameRevenueRatio
United States260.5K100.00%
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +8.11%
Sample Name
Sample Code
 +7.67%
Sample Name
Sample Code
 +5.06%
4
ProShares Ultra Bloomberg Crude Oil ETF
UCO
+4.18%
5
United States Gasoline Fund Lp
UGA
+2.58%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +26.23%
Sample Name
Sample Code
 +21.09%
Sample Name
Sample Code
 +18.00%
4
Hesai
HSAI
+16.00%
5
Futu Holdings Ltd
FUTU
+14.80%
View More
Middle East conflict spreads to the stock market! How should investors respond?
US President Trump stated in a recent interview that the US war with Iran has 'ended.' According to Axios, Pakistan, Egypt, and Turkey have Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -